Arrowhead Pharmaceuticals, Inc. (ARWR)
ARWR Stock Price Chart
Explore Arrowhead Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ARWR price movements and trends.
ARWR Company Profile
Discover essential business fundamentals and corporate details for Arrowhead Pharmaceuticals, Inc. (ARWR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Dec 1993
Employees
609.00
Website
https://arrowheadpharma.comCEO
Christopher R. Anzalone
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
ARWR Financial Timeline
Browse a chronological timeline of Arrowhead Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 9 Feb 2026
Upcoming earnings on 25 Nov 2025
EPS estimate is -$0.16.
Earnings released on 7 Aug 2025
EPS came in at -$1.26 falling short of the estimated -$0.94 by -34.04%, while revenue for the quarter reached $27.77M , missing expectations by -82.18%.
Earnings released on 12 May 2025
EPS came in at $2.75 surpassing the estimated -$0.06 by +4.68K%, while revenue for the quarter reached $542.71M , beating expectations by +366.77%.
Earnings released on 10 Feb 2025
EPS came in at -$1.39 falling short of the estimated -$0.42 by -230.95%, while revenue for the quarter reached $2.50M , missing expectations by -86.88%.
Earnings released on 26 Nov 2024
EPS came in at -$1.38 falling short of the estimated -$1.05 by -31.43%, while revenue for the quarter reached $3.55M , missing expectations by -93.55%.
Earnings released on 8 Aug 2024
EPS came in at -$1.38 falling short of the estimated -$0.58 by -137.93%.
Earnings released on 9 May 2024
EPS came in at -$1.02 falling short of the estimated -$0.06 by -1.60K%.
Earnings released on 6 Feb 2024
EPS came in at -$1.24 falling short of the estimated -$0.78 by -58.97%, while revenue for the quarter reached $3.55M , missing expectations by -87.97%.
Earnings released on 29 Nov 2023
EPS came in at -$1.03 falling short of the estimated -$0.70 by -47.14%, while revenue for the quarter reached $16.10M , missing expectations by -68.27%.
Earnings released on 7 Aug 2023
EPS came in at -$0.96 falling short of the estimated -$0.58 by -65.52%, while revenue for the quarter reached $15.83M , missing expectations by -73.55%.
Earnings released on 2 May 2023
EPS came in at $0.45 surpassing the estimated -$0.64 by +170.31%, while revenue for the quarter reached $146.27M , beating expectations by +221.61%.
Earnings released on 6 Feb 2023
EPS came in at -$0.39 falling short of the estimated $1.14 by -134.21%, while revenue for the quarter reached $62.55M , missing expectations by -61.51%.
Earnings released on 28 Nov 2022
EPS came in at -$0.81 falling short of the estimated -$0.57 by -42.11%, while revenue for the quarter reached $31.58M , missing expectations by -37.22%.
Earnings released on 4 Aug 2022
EPS came in at -$0.68 falling short of the estimated -$0.45 by -51.11%, while revenue for the quarter reached $32.41M , missing expectations by -29.16%.
Earnings released on 10 May 2022
EPS came in at $0.41 surpassing the estimated -$0.08 by +612.50%, while revenue for the quarter reached $151.81M , beating expectations by +24.28%.
Earnings released on 2 Feb 2022
EPS came in at -$0.60 falling short of the estimated -$0.22 by -172.73%, while revenue for the quarter reached $27.44M , missing expectations by -42.61%.
Earnings released on 22 Nov 2021
EPS came in at -$0.61 falling short of the estimated -$0.11 by -478.47%, while revenue for the quarter reached $38.28M , beating expectations by +2.83%.
Earnings released on 5 Aug 2021
EPS came in at -$0.29 falling short of the estimated -$0.08 by -262.50%, while revenue for the quarter reached $45.89M , beating expectations by +22.31%.
Earnings released on 4 May 2021
EPS came in at -$0.26 falling short of the estimated -$0.09 by -188.89%, while revenue for the quarter reached $32.81M , missing expectations by -12.97%.
Earnings released on 4 Feb 2021
EPS came in at -$0.20 falling short of the estimated $1.00 by -120.00%, while revenue for the quarter reached $21.30M , missing expectations by -73.19%.
Earnings released on 23 Nov 2020
EPS came in at -$0.48 falling short of the estimated $0.34 by -241.18%, while revenue for the quarter reached $7.63M , missing expectations by -81.48%.
ARWR Stock Performance
Access detailed ARWR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.